<DOC>
	<DOCNO>NCT00946556</DOCNO>
	<brief_summary>Herpes simplex virus type 2 ( HSV2 ) , common cause genital herpes , increase woman 's risk HIV acquisition 3-6 fold , perhaps HSV2-infected woman increase number HIV `` target cell '' ( CD4 T cell dendritic cell ) cervical mucosa . However , recent clinical trial show impact HSV2 suppression HIV acquisition rate . The reason negative result unclear . The investigator propose examine effect valacyclovir ( widely use herpes medication ) treatment cervical immunology HIV target cell cervix . The study take form randomize , double-blind , placebo-controlled crossover trial . Primary endpoint ( 1 ) number CD4 T cell cervical cytobrush ( 2 ) number immature dendritic cell per cervical cytobrush .</brief_summary>
	<brief_title>Examining Ability Herpes Simplex Virus Type 2 ( HSV2 ) Therapy Reduce HIV Target Cell Numbers Cervix</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Female HSV2 infect HIV infect Pregnant Taking HSV2 therapy Current/recent ( past 3 month ) genital infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>herpes simplex virus type 2</keyword>
	<keyword>HIV</keyword>
	<keyword>genital immunology</keyword>
	<keyword>CD4+ T cell</keyword>
	<keyword>valacyclovir</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>